新型喹诺酮抗菌剂司帕沙星（AT-4140和CI-978）对嗜血杆菌和革兰氏阳性球菌的体外活性。
In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
作者信息
Rudrik J T, Ferrigno S R, Gee S L
机构信息
Laboratory Service, Veteran Affairs Medical Center, Asheville, North Carolina 28805.
出版信息
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):355-60. doi: 10.1016/0732-8893(91)90028-e.
Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci, Enterococcus faecalis, anaerobic Gram-positive cocci, and Haemophilus sp. The MIC of sparfloxacin for greater than 93% of the strains tested was less than or equal to 0.5 microgram/ml. Sparfloxacin demonstrated increased activity against enterococci, staphylococci, pneumococci, and anaerobic cocci when compared with ciprofloxacin.
对司帕沙星（AT - 4140和CI - 978）针对194株葡萄球菌、链球菌、粪肠球菌、厌氧革兰氏阳性球菌及嗜血杆菌属的临床分离株的活性进行了评估。司帕沙星对超过93%的受试菌株的最低抑菌浓度小于或等于0.5微克/毫升。与环丙沙星相比，司帕沙星对肠球菌、葡萄球菌、肺炎球菌及厌氧球菌表现出更强的活性。
Zotero 插件